Navigation Links
BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
Date:2/29/2012

LYNBROOK, N.Y., Feb. 29, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that BioSpecifics' President, Tom Wegman, will present at the following upcoming investor conferences during the month of March 2012.

  • Cowen and Company 32nd Annual Health Care Conference (Boston, MA)
    Wednesday, March 7, 2012 at 10:40 a.m. EST
  • ROTH Capital Partners 24th Annual Conference (Laguna Niguel, CA)
    Tuesday, March 13, 2012 at 3:30 p.m. PDT (6:30 p.m. EDT)

The live webcasts of these presentations can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Its partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture in adults with a palpable cord in the palm and is also developing XIAFLEX for the treatment of Peyronie's disease, which is currently in Phase 3 pivotal clinical trials, as well as for Frozen Shoulder (Adhesive Capsulitis) and cellulite which are in Phase 2 and Phase 1 respectively. Pfizer, Inc. is responsible for marketing XIAPEX® for Dupuytren's contracture in the 27 European Union member countries and 19 other European and Eurasian countries and also has commercialization and development rights for Peyronie's disease in these same territories. Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan and Actelion Pharmaceuticals has the development, supply and commercialization rights in Canada, Australia, Brazil and Mexico. BioSpecifics is developing XIAFLEX internally for human and canine lipomas. More information about the Company may be found on its website at www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2011 Financial Results on November 8, 2011
3. BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting
4. BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results
5. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results
6. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2010 Financial Results on March 11, 2011
7. BioSpecifics Technologies Corp. to Present at Cowen and Company 31st Annual Health Care Conference
8. BioSpecifics Announces Positive Results From Clinical Trial in Canine Lipomas
9. BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
10. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
11. Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... ... and Electrospraying line of nanofiber and nanoparticle fabrication instruments ... the lab to fully automated pilot plants and equipment for industrial manufacturing. ...
(Date:8/16/2017)... ... August 16, 2017 , ... We are proud ... (FDA) inspection at our Dilworth, MN site. The inspection took place Monday, July ... conducted as part of a routine Bioresearch Monitoring Program (BIMO) with the USFDA ...
(Date:8/15/2017)... ... August 15, 2017 , ... Kapstone Medical is proud to ... helping medical technology companies and inventors develop and safeguard their latest innovations. The ... firm with a portfolio of clients in the United States and around the world. ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... ... new family of 6” modular downlights designed to stay tightly sealed and perform ... areas where damp and wet location listings just aren't enough, such as: hospitals; ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
Breaking Biology News(10 mins):